Ifosfamide

Generic Name
Ifosfamide
Brand Names
Ifex
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
3778-73-2
Unique Ingredient Identifier
UM20QQM95Y
Background

Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication

Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...

Associated Conditions
Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
Associated Therapies
-
Clinical Trials
Related News

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

First Posted Date
2015-03-20
Last Posted Date
2024-05-29
Lead Sponsor
Amgen
Target Recruit Count
111
Registration Number
NCT02393859
Locations
🇬🇧

Research Site, Sutton, United Kingdom

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

First Posted Date
2015-03-19
Last Posted Date
2023-10-26
Lead Sponsor
New York Medical College
Target Recruit Count
25
Registration Number
NCT02393157
Locations
🇺🇸

New York Medical College, Valhalla, New York, United States

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

First Posted Date
2015-03-02
Last Posted Date
2023-08-31
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
420
Registration Number
NCT02375204
Locations
🇺🇸

Loma Linda University Medical Center, Loma Linda, California, United States

🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 122 locations

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

First Posted Date
2015-01-28
Last Posted Date
2024-06-04
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
307
Registration Number
NCT02348216
Locations
🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

🇺🇸

University of California Los Angeles (UCLA), Santa Monica, California, United States

🇨🇦

Princess Margaret, Toronto, Ontario, Canada

and more 33 locations

New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

First Posted Date
2014-12-31
Last Posted Date
2024-07-29
Lead Sponsor
International Extranodal Lymphoma Study Group (IELSG)
Target Recruit Count
76
Registration Number
NCT02329080
Locations
🇮🇹

IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy

🇮🇹

Villa Sofia - Cervello, Palermo, Italy

🇨🇿

Facultni nemocnice, Brno, Czechia

and more 33 locations

PEI REGIMEN: A Therapeutic Option in Small Cell Lung Cancer? A Monoinstitutional Experience of 46 Consecutive Cases

Completed
Conditions
Small Cell Lung Cancer
First Posted Date
2014-12-24
Last Posted Date
2014-12-24
Lead Sponsor
Arcispedale Santa Maria Nuova-IRCCS
Target Recruit Count
46
Registration Number
NCT02324296

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

First Posted Date
2014-12-03
Last Posted Date
2024-12-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
312
Registration Number
NCT02306161
Locations
🇺🇸

Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States

🇺🇸

Springfield Memorial Hospital, Springfield, Illinois, United States

🇺🇸

Henry Ford Health Saint John Hospital, Detroit, Michigan, United States

and more 313 locations

International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

First Posted Date
2014-12-02
Last Posted Date
2024-06-04
Lead Sponsor
Institute of Cancer Research, United Kingdom
Target Recruit Count
200
Registration Number
NCT02305654
Locations
🇺🇸

Los Angeles County-USC Medical Center, Los Angeles, California, United States

🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Grady Health System, Atlanta, Georgia, United States

and more 14 locations

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

First Posted Date
2014-08-28
Last Posted Date
2024-02-15
Lead Sponsor
University of Washington
Target Recruit Count
45
Registration Number
NCT02227199
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

First Posted Date
2014-08-19
Last Posted Date
2018-01-26
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
26
Registration Number
NCT02219737
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy